A Palo Alto SaaS company quietly moving the world's clinical trials out of the hospital basement and into the patient's pocket.
On a Tuesday morning in a small town in Iowa, a 67-year-old retired teacher with early-stage Parkinson's taps a green button on her phone. She records a 30-second voice memo, answers six questions, and her wearable uploads last night's tremor data. She is, at that moment, a participant in a Phase III clinical trial run by a global pharmaceutical company. She has not driven anywhere. She has not signed a paper form. She has not, in fact, met anyone in person about this study at all. The software making this possible is Medable.
For most of the twentieth century, the clinical trial was a building. You drove to it. You parked. You sat under fluorescent light and filled in a clipboard. If you lived in a city near an academic medical center, you had options. If you lived almost anywhere else, you did not. The medicine industry called this "patient recruitment." Patients had a less charitable word for it.
It costs roughly $2 billion and a decade to bring a new drug from a chemist's notebook to a pharmacy shelf. About 30 percent of that cost - and most of the delay - lives inside the clinical trial phase. The reason is not science. The reason is logistics. Trials drop participants because driving forty miles to a study site every other week is, it turns out, a lot to ask. Trials skew toward people who live near research hospitals, which is to say toward a narrow and unrepresentative slice of humanity. Trials run on paper, and paper takes time, and time is - the saying goes - patients.
By the mid-2010s, every major pharmaceutical company knew this. Most of them had spent years writing strategy decks about "decentralizing" trials. The decks were excellent. The execution was not.
Dr. Michelle Longmire was, by training, a Stanford-credentialed physician-scientist with a focus on dermatology. She was not, by training, a SaaS founder. This turned out to matter less than people thought. Longmire had spent enough hours inside trial protocols to know exactly where the friction lived. In 2015, with co-founder Tim Smith, she started Medable on a hunch - that if you rebuilt the clinical trial as software, sponsors would eventually have to use it. Not because they wanted to. Because the economics would force them.
For the first few years, the hunch did not look brilliant. Pharma is conservative. Regulators are more conservative. The phrase "decentralized clinical trial" was, in 2017, mostly used as a punchline at conferences in San Diego.
Then, in March 2020, every clinical trial in the world stopped at the same time. Sponsors who had ignored Medable's sales pitch for three years now called back inside a week. AstraZeneca, among others, leaned on Medable's platform to keep studies moving while research sites went dark. By the end of that year, Medable had become something the industry could not quite ignore: useful.
Medable is not one app. It is four interlocking modules sold as a single cloud platform - the unsexy infrastructure that turns a 600-page trial protocol into something a patient can actually do from a couch.
Electronic Clinical Outcome Assessments. The patient diary, on a phone, in 120 languages, validated for regulators.
eConsent that replaces the multi-page paper form with an experience patients can actually read, in the clinic or at home.
Connects wearables and at-home devices so trials can collect data continuously, not just on visit days.
Built-in telemedicine for site-to-patient visits, integrated with the rest of the trial record.
In late 2024 the company added Medable Studio - a no-code, AI-assisted builder that lets sponsors stand up a new eCOA in days instead of months. The promise is the same one Salesforce made about customer records and Stripe made about payments: take a slow, custom-built, agency-fueled process and turn it into a software workflow. The targets are different. The math is identical.
The numbers are the most persuasive part of the story, and they are not subtle. Medable's platform now sits underneath the trial operations of 14 of the world's 20 largest pharmaceutical companies and 9 of the top 10 contract research organizations. The platform has powered more than 300 decentralized and hybrid studies across 60-plus countries. Over a million patients have interacted with it - most of them with no idea they were on a "SaaS product."
Reported outcomes from Medable-deployed decentralized and hybrid trials.
The kind of figures pharma CFOs write down and email to each other.
The recognition followed. The Prix Galien - sometimes called the Nobel of biomedicine - has gone to Medable twice in two years, first in the US in 2023 and then in the UK in 2024. Everest Group put the company in the Leader quadrant of its 2025 eCOA assessment. Investors have parked roughly half a billion dollars in the company across four funding rounds, including a $304 million Series D in October 2021 that valued the business at around $2.1 billion.
The official line from the company is concise: get effective therapies to patients faster by giving anyone, anywhere access to clinical research. It is the rare mission statement that survives translation into a CFO memo. Every part of the Medable platform is, at root, an argument against the assumption that a trial has to look the way it has always looked.
That argument is also about who gets included. Traditional trials skew white, urban, and able-bodied because that is who lives near the buildings. A trial run through Medable can recruit a patient in rural Tennessee, suburban Sao Paulo, and inner-city Tokyo with the same software. This is not a marketing slide. It is a regulatory expectation - the FDA's 2024 diversity action plan guidance assumes trials will look more like the population that will eventually take the drug. Decentralized infrastructure is one of the few realistic ways to get there.
The arc Medable is betting on is unglamorous and probably correct. Over the next decade, the clinical trial stops being a thing you go to and becomes a thing that runs in the background of life - more like a banking app than a hospital visit. Sensor data replaces the once-a-month blood draw. Agentic AI inside platforms like Medable Studio writes a first-draft trial protocol that a clinician then edits. The cost curve bends. The diversity gap narrows. Drugs reach the market faster.
Whether Medable is the company that ends up owning that arc is, of course, an open question. Veeva, Signant, Clario, and a handful of well-funded upstarts would all like a piece of it. The competitive race is real. But the underlying trend - software eating the trial - is no longer in doubt. Medable spent the better part of a decade making sure of that.
Back in Iowa, the retired teacher finishes her morning check-in and sets her phone down. The trial she is in will, with luck, lead to a drug that slows Parkinson's disease for the next person in her town who gets it. She does not need to drive anywhere to make that happen. That part used to be impossible. Now it is just a Tuesday.